There’s a reason lots of companies are working on GLP-1-based drugs for obesity: The other stuff tends not to work. The latest biotech to learn this the hard way is Wave Life Sciences, which
Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program
Plus, news about Astellas’ setidegrasib and Anavex: 📈 Kodiak’s eye drug win: The biotech’s experimental drug Zenkuda, whose scientific name is tarcocimab tedromer, beat a


